Key result
Cardiovascular autonomic neuropathy is linked to ~64% higher mortality in women with type 2 diabetes.
Why the study?
The effect of sex on the association between cardiovascular autonomic neuropathy and mortality in patients with type 2 diabetes was unknown.
Does the presence of cardiovascular autonomic neuropathy increase the risk of all-cause and cardiovascular mortality differently between women and men with type 2 diabetes?
Cohort (n=7,866)
Yes
Does the presence of cardiovascular autonomic neuropathy increase the risk of all-cause and cardiovascular mortality differently between women and men with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Cardiovascular autonomic neuropathy is independently associated with a significantly higher risk of all-cause and cardiovascular mortality in women with type 2 diabetes, but not in men, highlighting the need for targeted autonomic screening and risk management in women.
Background Cardiovascular autonomic neuropathy (CAN) is a severe complication of type 2 diabetes. Significant sex‐related differences have been observed in type 2 diabetes consequences such as mortality. However, the effect of sex on the association between CAN and mortality in patients with type 2 diabetes is currently unknown. Methods and Results We assessed 7866 participants in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, including 4730 men and 3136 women. CAN was diagnosed using a combination of heart rate variability and QT interval index, which has 3 different definitions. There were 1364 cases of all‐cause mortality and 452 cases of cardiovascular disease mortality during a median follow‐up of 9.7 years. We used multivariable Cox regression models to assess the association between different CAN definitions and mortality. In women, various CAN measures were statistically significant associated with an increased risk of all‐cause mortality (CAN1: hazard ratio [HR], 1.64 [95% CI, 1.28–2.09]; CAN2: HR, 1.58 [95% CI, 1.17–2.15]; CAN3: HR, 1.78 [95% CI, 1.20–2.65]) and mortality (CAN1: HR, 2.25 [95% CI, 1.44–3.52]; CAN 2: HR, 2.22 [95% CI, 1.28–3.87]; CAN3: HR, 3.31 [95% CI, 1.67–6.57]). CAN was not significantly associated with mortality in men. A significant multiplicative interaction of CAN and sex was observed on both mortality outcomes ( P <0.01). Conclusions Significant sex‐related differences were observed in CAN and its associated mortality. In terms of mortality risk prevention, CAN should be given greater consideration in women with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted a cohort in Type 2 diabetes (n=7,866). Cardiovascular autonomic neuropathy (CAN1: SDNN <8.2 ms and rMSSD <8.0 ms) in women vs. Absence of cardiovascular autonomic neuropathy (CAN1) in women was evaluated on All-cause mortality in women (by CAN1 status) (HR 1.64, 95% CI 1.28-2.09, p=<0.001). Cardiovascular autonomic neuropathy (CAN1) was associated with higher all-cause mortality in women with type 2 diabetes, but not in men.
Synapse has enriched 10 related papers. Consider them for comparative context: